SKYE

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Skye Bioscience, Inc. Common Stock

NASDAQ | SKYE

1.12

USD

$0.00

(

0.00%

)

At Close (As of Dec 12, 2025)

$36.87M

Market Cap

-

P/E Ratio

-1.3

EPS

$5.75

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

SKYE Chart

Recent Chart
Price Action

SKYE Technicals

Tags:

SKYE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$299K
Total Revenue $0
Cost Of Revenue $299K
Costof Goods And Services Sold $299K
Operating Income -$30M
Selling General And Administrative $18M
Research And Development $19M
Operating Expenses $30M
Investment Income Net -
Net Interest Income $2.3M
Interest Income $3.3M
Interest Expense $968K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $299K
Income Before Tax -$27M
Income Tax Expense $10K
Interest And Debt Expense -
Net Income From Continuing Operations -$27M
Comprehensive Income Net Of Tax -
Ebit -$26M
Ebitda -$25M
Net Income -$27M

Revenue & Profitability

Earnings Performance

SKYE Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $73M
Total Current Assets $71M
Cash And Cash Equivalents At Carrying Value $68M
Cash And Short Term Investments $68M
Inventory -
Current Net Receivables $5.1K
Total Non Current Assets $1.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.4M
Other Non Current Assets -
Total Liabilities $4.6M
Total Current Liabilities $4.3M
Current Accounts Payable $569K
Deferred Revenue -
Current Debt -
Short Term Debt $182K
Total Non Current Liabilities $273K
Capital Lease Obligations $456K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $456K
Other Current Liabilities $3.6M
Other Non Current Liabilities -
Total Shareholder Equity $68M
Treasury Stock -
Retained Earnings -$131M
Common Stock $31K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$25M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $299K
Capital Expenditures $1.6M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$246K
Cashflow From Financing $84M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$27M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$299K
Total Revenue $0
Cost Of Revenue $299K
Costof Goods And Services Sold $299K
Operating Income -$30M
Selling General And Administrative $18M
Research And Development $19M
Operating Expenses $30M
Investment Income Net -
Net Interest Income $2.3M
Interest Income $3.3M
Interest Expense $968K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $299K
Income Before Tax -$27M
Income Tax Expense $10K
Interest And Debt Expense -
Net Income From Continuing Operations -$27M
Comprehensive Income Net Of Tax -
Ebit -$26M
Ebitda -$25M
Net Income -$27M

SKYE News

SKYE Profile

Skye Bioscience, Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to unlocking the therapeutic potential of the endocannabinoid system. The company is developing a robust pipeline of cannabinoid-based therapies targeting unmet medical needs in various therapeutic areas, including glaucoma, pain management, and inflammation. With a focus on scientific innovation and rigorous clinical research, Skye aims to position itself as a leader in the biopharmaceutical landscape, contributing to the advancement of effective and patient-focused treatment options.

LPTX
+368.57%
$2.05
PAVS
+21.15%
$0.04
YCBD
+102.85%
$1.28
YGMZ
-61.42%
$0.02
OCG
+261.14%
$3.29
NVDA
-2.13%
$177.07
CGC
+46.02%
$1.65
WOK
-28.86%
$0.11
RIVN
+16.21%
$19.09
KIND
+9.48%
$2.77
AXDX
-61.36%
$0.03
ATPC
-25.44%
$0.13
PLUG
+1.69%
$2.40
TSLA
+0.84%
$450.67
TLRY
+35.47%
$11.42
KAVL
-16.35%
$0.16
AVGO
-10.83%
$362.33
TNYA
-33.66%
$0.90
FRMI
-32.49%
$10.29
ADAP
-15.14%
$0.05
ASST
-2.40%
$0.89
ZDGE
+30.45%
$3.17
AKAN
+19.31%
$0.93
SOND
-23.45%
$0.12
ONDS
+0.56%
$9.07
VIVK
+0.40%
$0.07
INTC
-2.61%
$38.47
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
SRM
+53.27%
$10.30
TE
-9.62%
$5.30
SOFI
+1.14%
$27.38
PLTD
+1.90%
$6.44
WULF
-6.79%
$14.75
DNN
-5.80%
$2.59
APLT
-44.12%
$0.12
IRBT
-10.63%
$4.46
BMNR
-5.75%
$36.17
MTSR
-0.35%
$70.50
RR
-8.65%
$4.27
ASBP
-7.84%
$0.09
MARA
-2.01%
$11.60
FI
+2.38%
$68.16
NFLX
+1.34%
$95.35
PLTR
-2.75%
$182.37
F
+1.02%
$13.76
VALE
-4.55%
$12.68
AFMD
-34.94%
$0.18
RZLT
+9.32%
$1.53
CRWV
-8.46%
$79.97
RKLB
+0.29%
$63.72
BITF
-5.95%
$2.76
CLSK
-2.64%
$14.42
IVP
-6.59%
$0.04
AMD
-3.52%
$213.63
AAL
+0.70%
$15.06
TWOH
0.00%
$0.00
GOOGL
-0.85%
$309.75
HOOD
-2.10%
$120.78
GRYP
-10.38%
$1.38
SNAP
-1.89%
$7.49
CAN
-6.61%
$0.86
BBD
+1.31%
$3.45
MODV
-25.22%
$0.43
KPLT
+20.87%
$7.50
CIFR
-6.54%
$17.64
SOUN
-0.46%
$11.97
AMZN
-1.66%
$226.45
NIO
0.00%
$5.13
BTG
-1.82%
$4.59
WBD
+1.30%
$29.87
QBTS
-5.71%
$26.38
PFE
+0.66%
$25.97
HL
-3.85%
$18.60
ABEV
+1.40%
$2.53
ACHR
-3.79%
$8.23
NXDR
-9.11%
$2.51
RIG
-1.75%
$4.20
AG
-6.39%
$15.73
IBRX
+11.41%
$2.44
MU
-4.88%
$245.82
BAC
+1.07%
$55.14
CDE
-2.64%
$17.01
BYND
-3.34%
$1.14
RGTI
-6.54%
$25.12
AAPL
+0.19%
$278.57
SHOT
-74.37%
$0.39
LULU
+10.12%
$205.93
APLD
-6.47%
$28.76
ZAPP
-46.30%
$0.15
BTBT
-7.47%
$2.27
BLNK
-9.93%
$0.79
T
+1.50%
$24.66
PCG
+3.10%
$15.29
CRCG
-13.05%
$2.93
ORCL
-3.57%
$191.74
GPUS
-4.61%
$0.27
ASTS
-7.92%
$78.03
BE
-7.65%
$100.65
LPTX
+368.57%
$2.05
PAVS
+21.15%
$0.04
YCBD
+102.85%
$1.28
YGMZ
-61.42%
$0.02
OCG
+261.14%
$3.29
NVDA
-2.13%
$177.07
CGC
+46.02%
$1.65
WOK
-28.86%
$0.11
RIVN
+16.21%
$19.09
KIND
+9.48%
$2.77
AXDX
-61.36%
$0.03
ATPC
-25.44%
$0.13
PLUG
+1.69%
$2.40
TSLA
+0.84%
$450.67
TLRY
+35.47%
$11.42
KAVL
-16.35%
$0.16
AVGO
-10.83%
$362.33
TNYA
-33.66%
$0.90
FRMI
-32.49%
$10.29
ADAP
-15.14%
$0.05
ASST
-2.40%
$0.89
ZDGE
+30.45%
$3.17
AKAN
+19.31%
$0.93
SOND
-23.45%
$0.12
ONDS
+0.56%
$9.07
VIVK
+0.40%
$0.07
INTC
-2.61%
$38.47
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
SRM
+53.27%
$10.30
TE
-9.62%
$5.30
SOFI
+1.14%
$27.38
PLTD
+1.90%
$6.44
WULF
-6.79%
$14.75
DNN
-5.80%
$2.59
APLT
-44.12%
$0.12
IRBT
-10.63%
$4.46
BMNR
-5.75%
$36.17
MTSR
-0.35%
$70.50
RR
-8.65%
$4.27
ASBP
-7.84%
$0.09
MARA
-2.01%
$11.60
FI
+2.38%
$68.16
NFLX
+1.34%
$95.35
PLTR
-2.75%
$182.37
F
+1.02%
$13.76
VALE
-4.55%
$12.68
AFMD
-34.94%
$0.18
RZLT
+9.32%
$1.53
CRWV
-8.46%
$79.97
RKLB
+0.29%
$63.72
BITF
-5.95%
$2.76
CLSK
-2.64%
$14.42
IVP
-6.59%
$0.04
AMD
-3.52%
$213.63
AAL
+0.70%
$15.06
TWOH
0.00%
$0.00
GOOGL
-0.85%
$309.75
HOOD
-2.10%
$120.78
GRYP
-10.38%
$1.38
SNAP
-1.89%
$7.49
CAN
-6.61%
$0.86
BBD
+1.31%
$3.45
MODV
-25.22%
$0.43
KPLT
+20.87%
$7.50
CIFR
-6.54%
$17.64
SOUN
-0.46%
$11.97
AMZN
-1.66%
$226.45
NIO
0.00%
$5.13
BTG
-1.82%
$4.59
WBD
+1.30%
$29.87
QBTS
-5.71%
$26.38
PFE
+0.66%
$25.97
HL
-3.85%
$18.60
ABEV
+1.40%
$2.53
ACHR
-3.79%
$8.23
NXDR
-9.11%
$2.51
RIG
-1.75%
$4.20
AG
-6.39%
$15.73
IBRX
+11.41%
$2.44
MU
-4.88%
$245.82
BAC
+1.07%
$55.14
CDE
-2.64%
$17.01
BYND
-3.34%
$1.14
RGTI
-6.54%
$25.12
AAPL
+0.19%
$278.57
SHOT
-74.37%
$0.39
LULU
+10.12%
$205.93
APLD
-6.47%
$28.76
ZAPP
-46.30%
$0.15
BTBT
-7.47%
$2.27
BLNK
-9.93%
$0.79
T
+1.50%
$24.66
PCG
+3.10%
$15.29
CRCG
-13.05%
$2.93
ORCL
-3.57%
$191.74
GPUS
-4.61%
$0.27
ASTS
-7.92%
$78.03
BE
-7.65%
$100.65
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.